Online citations, reference lists, and bibliographies.

Adherence Of Multiple Myeloma Cells To Bone Marrow Stromal Cells Upregulates Vascular Endothelial Growth Factor Secretion: Therapeutic Applications

D Gupta, Sp Treon, Yoichiro Shima, Teru Hideshima, Klaus Podar, Yt Tai, Baojue Lin, Suzanne Lentzsch, Fe Davies, Dharminder Chauhan, R Schlossman, P. Richardson, Parchment Ralph, L Wu, Faribourz Payvandi, G. Muller, DI Stirling, K C Anderson
Published 2001 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Increased angiogenesis has recently been recognized in active multiple myeloma (MM). Since vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) are two key mediators of angiogenesis, we characterized the production of VEGF, b-FGF and interleukin-6 (IL-6) (a MM growth and survival factor) in MM cell lines and Epstein–Barr virus (EBV) transformed B cell lines from MM patients, patient MM cells, as well as bone marrow stromal cells (BMSCs) from normal healthy donors and MM patients. We detected secretion of VEGF, but no bFGF and IL-6, in MM cell lines (MM.1S, RPMI 8226 and U266); EBV transformed B cell lines from MM patients (IM-9, HS-Sultan and ARH77); MM cell lines resistant to doxorubicin (RPMI-DOX40), mitoxantrone (RPMI-MR20), melphalan (RPMI-LR5) and dexamethasone (MM.1R); and patient MM cells (MM1 and MM2). BMSCs from MM patients and normal donors secreted VEGF, b-FGF and IL-6. Importantly, when MM cells were adhered to BMSCs, there was a significant increase in VEGF (1.5- to 3.1-fold) and IL-6 (1.9- to 56-fold) secretion. In contrast, the bFGF decreased in co-cultures of BMSCs and MM cells. Paraformaldehyde fixation of BMSCs or MM cells prior to adhesion revealed that VEGF was produced both from BMSCs and MM cells, though it may come primarily from BMSCs in some cultures. IL-6 was produced exclusively in BMSCs, rather than MM cells. Moreover, when MM cells were placed in Transwell insert chambers to allow their juxtaposition to BMSCs without cell to cell contact, induction of VEGF and IL-6 secretion persisted, suggesting the importance of humoral factors. Addition of exogenous IL-6 (10 ng/ml) increased VEGF secretion by BMSCs. Conversely, VEGF (100 ng/ml) significantly increased IL-6 secretion by BMSCs. Moreover, anti-human VEGF (1 μg/ml) and anti-human IL-6 (10 μg/ml) neutralizing antibodies reduced IL-6 and VEGF secretion, respectively, in cultures of BMSCs alone and co-cultures of BMSCs and MM cells. Finally, thalidomide (100 μM) and its immunomodulatory analog IMiD1-CC4047 (1 μM) decreased the upregulation of IL-6 and VEGF secretion in cultures of BMSCs, MM cells and co-cultures of BMSCs with MM cells. These data demonstrate the importance of stromal–MM cell interactions in regulating VEGF and IL-6 secretion, and suggest additional mechanisms whereby thalidomide and IMiD1-CC4047 act against MM cells in the BM millieu.
This paper references
Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma
Domenico Ribatti (1999)
Therapy with thalidomide in refractory multiple myeloma patients - the revival of an old drug.
Abraham Kneller (2000)
Human vascular permeability factor. Isolation from U937 cells.
Daniel T. Connolly (1989)
Cancer statistics, 2000.
Robert T Greenlee (2000)
Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration.
Klaus Podar (2001)
Antitumor activity of thalidomide in refractory multiple myeloma.
S Singhal (1999)
Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies.
William T. Bellamy (1999)
Angiogenesis in newly diagnosed multiple myeloma: poor prognosis with increased microvessel density (MVD) in bone marrow biopsies
N Munshi (1998)
Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent
Athanasios Zomas (2000)
Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia.
Walter Fiedler (1997)
The cell surface proteoglycan syndecan-1 mediates fibroblast growth factor-2 binding and activity.
Mark S. Filla (1998)
Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes.
Álvaro Aguayo (2000)
Thalidomide is an inhibitor of angiogenesis.
Robert J D'Amato (1994)
Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma.
Berno Dankbar (2000)
Basic fibroblast growth factor-syndecan complex at cell surface or immobilized to matrix promotes cell growth.
Markku Salmivirta (1992)
The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor.
C de Vries (1992)
Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
Francesco Di Raimondo (2000)
Low - dose thalidomide in the treatment of refractory myel
M Pini (2000)
Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells.
Mitsuyoshi Urashima (1996)
Angiogenic factors.
Judah Folkman (1987)
Multiple myeloma: increasing our treatment options.
Melissa Alsina (2003)
Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias.
Régis Bataille (1989)
Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer.
Yusuke Ohta (1996)
Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract.
Lawrence F. Brown (1993)
Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma.
Noel Weidner (1991)
Low-dose of thalidomide in the treatment of refractory myeloma.
Massimo Pini (2000)
Growth factors in POEMS syndrome: evidence for a marked increase in circulating vascular endothelial growth factor.
Martin Soubrier (1997)
Multiple myeloma: increasing evidence for a multistep transformation process.
Michael Hallek (1998)
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.
Teru Hideshima (2000)
myeloma cells
R Bataille (1997)
Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells.
Dharminder Chauhan (1997)
Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia.
Álvaro Aguayo (1999)
Syndecan-1 (CD 138) in myeloma and lymphoid malignancies: a multifunctional regulator of cell behavior within the tumor microenvironment.
Madhav V Dhodapkar (1999)
Regulation of interleukin 6 in multiple myeloma and bone marrow stromal cells.
Dharminder Chauhan (1995)
Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6.
Bernard Klein (1989)
Interleukin-6 in human multiple myeloma.
Bernard Klein (1995)
Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients.
Luc Y Dirix (1997)
Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B.
Dharminder Chauhan (1996)
Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers.
M Nguyen (1994)
Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma
S. Vincent Rajkumar (1999)
Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma.
Noel Weidner (1993)
Thalidomide--a revival story.
Nishita Raje (1999)
IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade.
Atsushi Ogata (1997)
Tumor angiogen
N Weidner (1995)
Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha.
Laura G. Corral (1999)
Long-term culture of human bone marrow cells.
Samuel Gartner (1980)
Clinical applications of research on angiogenesis
Judah Folkman (1995)
Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma.
Dafna Meitar (1996)
Autocrine generation and essential requirement of BSF2 / IL - 6 for human multiple myeloma
M Kawano (1988)
Prognostic value of angiogenesis in operable non-small cell lung cancer.
Alexandra Giatromanolaki (1996)
Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion.
Hiroshi Uchiyama (1993)
Angiogenesis spectrum in the stroma of B-cell non-Hodgkin's lymphomas. An immunohistochemical and ultrastructural study.
Domenico Ribatti (1996)
Thalidomide in the treatment of relapsed multiple myeloma.
Sundararajan Vincent Rajkumar (2000)
Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma.
Gunnar Juliusson (2000)
Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue.
I B Joseph (1997)
Basic fibroblast growth factor serum levels in multiple myeloma patients correlate with stage of disease and lapse under therapy
O Sezer (1999)
Prognostic value of bone marrow angiogenesis in multiple myeloma.
Sundararajan Vincent Rajkumar (2000)
Response patterns of purified myeloma cells to hematopoietic growth factors.
Kenneth C. Anderson (1989)

This paper is referenced by
Population Pharmacokinetics of Pomalidomide
Yan Li (2015)
Dihydrocelastrol inhibits multiple myeloma cell proliferation and promotes apoptosis through ERK1/2 and IL-6/STAT3 pathways in vitro and in vivo
Liangning Hu (2017)
NRF2 Is One of the Players Involved in Bone Marrow Mediated Drug Resistance in Multiple Myeloma
Chia-Hung Yen (2018)
Immunomodulatory drugs in myelodysplastic syndromes
Naomi Galili (2006)
Exosomes in Tumor Angiogenesis.
Karma Z. Salem (2016)
The biology of mantle cell lymphoma : exploring the gender difference in mantle cell lymphoma
Nimish Harshadrai Shah (2016)
Myeloma Resistance and is Well Tolerated in Patients with Relapse Multiple Immunomodulatory Derivative of Thalidomide CC-5013 Overcomes Drug
Kathe Balinski (2013)
New approach to evaluating the effects of a drug on protein complexes with quantitative proteomics, using the SILAC method and bioinformatic approach
Natsuki Kurokawa (2019)
Novel generation of agents with proven clinical activity in multiple myeloma.
María-Victoria Mateos (2013)
HGF, sIL-6R and TGF-β1 Play a Significant Role in the Progression of Multiple Myeloma
Artur Jurczyszyn (2014)
Induction of apoptosis in multiple myeloma cells by a statin-thalidomide combination can be enhanced by p38 MAPK inhibition.
Adrianna Sławińska-Brych (2013)
Current & Emerging Therapeutics for Multiple Myeloma
Noopur S. Raje (2013)
Lack of association between TNF-α promoter polymorphisms and multiple myeloma: a meta-analysis.
Bing Li (2013)
Bone Marrow Stroma and the Leukemic Microenvironment
William Birdsall Slayton (2010)
Lenalidomide in multiple myeloma: current role and future directions
Jerome Bernard Zeldis (2010)
Induction of miR-146a by multiple myeloma cells in mesenchymal stromal cells stimulates their pro-tumoral activity.
Kim De Veirman (2016)
Thalidomide as a targeted therapy for multiple myeloma.
Kazuo Dan (2003)
The role of the BM milieu in MM progression and therapeutic resistance
Matthew H. Ho (2020)
Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma.
Teru Hideshima (2003)
Thalidomide and dexamethasone: a new standard of care for initial therapy in multiple myeloma.
Paul Richardson (2006)
The clinical potential of proteasome inhibition
Kenneth C. Anderson (2004)
The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells.
Patricia Maiso (2008)
Cellular Mechanisms of Multiple Myeloma Bone Disease
Angela Oranger (2013)
Implication de l’Insulin-like Growth Factor (IGF-I), secrété par le microenvironnement tumoral, dans la survie et la chimiorésistance des cellules cancéreuses
Nadia Benabbou (2012)
Adaptation to survival in germinal center is the initial step in onset of indolent stage of multiple myeloma.
Ariosto Siqueira Silva (2011)
Management of multiple myeloma in the era of novel drugs.
Gordan Srkalović (2010)
Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo
Suzanne Lentzsch (2003)
Thalidomide: Mechanisms of Action
Taraneh Paravar (2008)
A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.
Robert Z. Orlowski (2015)
Bone Disease in Multiple Myeloma.
Homare Eda (2016)
Lenalidomide mode of action: linking bench and clinical findings.
Faith Davies (2010)
Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF
Angelo Corti (2010)
See more
Semantic Scholar Logo Some data provided by SemanticScholar